Walgreens Boots Alliance Inc

Walgreens Boots Alliance — Investor Day (October 2021)

113 slides from Walgreens Boots Alliance's investor day presentation, Oct 14, 2021

  1. Slide 1: Reimagining Healthcare for the next era

    Exhibit 99.2 Walgreens Boots Alliance ~" Reimagining Healthcare for the next era

  2. Slide 2: Safe Harbor and non-GAAP Cautionary Note Regarding Forward-Looking Statements

    Safe Harbor and non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in this presentation that are not historical including are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, witho

  3. Slide 3: Opening Remarks

    Opening Remarks Roz Brewer Chief Executive Officer WBA

  4. Slide 4: 2021 Investor Day agenda

    Walgreens Boots Alliance – 2021 Investor Day Opening Remarks Roz Brewer Our Purpose and Strategy John Standley Priorities Roz Brewer James Kehoe 4Q and Growth Model James Kehoe Closing Remarks Roz Brewer Q&A 4 © 2021 Walgreens Boots Alliance, Inc. All rights reserved.

  5. Slide 5: Reimagining Healthcare for the next era

    Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian

  6. Slide 6: Six months since joining: outside-in view

    no preconceived notions upon joining The past brought outside-in view 6 MONTHS of our assets have been a tremendous strengths… tremendous …great momentum and community relevance experience …but unclear strategy and disjointed culture © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 6

  7. Slide 7: Strong foundation of assets to build on

    Strong foundation of assets to build on Presence in healthcare more relevant than ever Tremendous momentum and future potential © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 7

  8. Slide 8: Validated the role of pharmacy in local communities

    Validated the role of pharmacy in local communities Completed Administered Completed more than more than more than 40 million 16 million 23 million COVID-19 COVID-19 tests same day orders vaccines to to date to date 8 © 2021 Walgreens Boots Alliance, Inc. All rights reserved. date

  9. Slide 9: Spent $500 million on vaccination and testing capabilities

    Spent $500 million to build and sustain capabilities and capacity to deliver the vaccination and testing programs 9 © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian nce, ce, I In nc. c. A All r ll rig igh ht ts s r re es se er rv ve ed d. .

  10. Slide 10: Reimagining Healthcare for the next era

    Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian

  11. Slide 11: 4Q21 U.S. retail highlights

    4Q21 U.S.: Created 6%+ retail differentiated comps omni-channel Personalization experiences 100%+ increase in digital sales to drive Engine digital and 85M+ physical traffic myWalgreens members 11 © 2021 Walgreens Boots Alliance, Inc. All rights reserved.

  12. Slide 12: Strengthened right to win within healthcare ecosystem

    Strengthened right to win within healthcare ecosystem Many assets to leverage… …and momentum as we more forward Reach in local communities (~9,000 U.S. locations) COVID-19 and underlying business Frequent touchpoints Partnerships and investments in payors with chronic customers and providers that wi

  13. Slide 13: Developed strong customer relationships and understanding

    Developed strong customer relationships and understanding Support Seekers Efficiency Enthusiasts 5+ Chronic No Chronic Conditions Conditions Wellness Watchers Concerned Caregivers 1-4 Chronic Caring for Themselves Conditions and a Loved One 13 © 2021 Walgreens Boots Alliance, Inc. All rights reserve

  14. Slide 14: 2022 will be a year of cultivating, sharpening, investing

    2022 will be a year of… CULTIVATING SHARPENING INVESTING our strengths our execution in our future 14 © 2021 Walgreens Boots Alliance, Inc. All rights reserved.

  15. Slide 15: Focus for today

    Focus for today PURPOSE Our Strategic Ambitions VISION Long-term Growth FY21 Earnings / FY22 Guidance VALUES 15 © 2021 Walgreens Boots Alliance, Inc. All rights reserved.

  16. Slide 16: Integrated healthcare, pharmacy and retail strategy key takeaways

    We have an integrated healthcare, pharmacy, and retail strategy, enabling sustainable, profitable growth We are well on our way to our new healthcare vision and ambition Key We are putting the right capabilities, assets and takeaways operating model in place from today We are committed to enhanced c

  17. Slide 17: Our Purpose, Vision and Values

    Our Purpose More joyful lives OUR Why we exist— our enduring North Star. WHY through better health. Our Vision To be the leading partner in reimagining OUR Our tangible, company-wide aspiration WHAT for the near-term. local healthcare and wellbeing for all. Our Values OUR Our shared beliefs and prin

  18. Slide 18: Our Vision

    OUR OUR Our Vision WHAT 1 WHAT Working alongside, and in service of, customers and providers 2 Looking beyond the status quo 1 to create unexpected solutions To be the leading partner 3 Serving the specific needs of each neighborhood 2 3 4 in reimagining local Healthcare: Supplying an entry point to

  19. Slide 19: Our Strategy: Advantaged growth in community healthcare

    OUR STRATEGY: Advantaged growth in community healthcare, while transforming our core Transform and align the core OUR VISION: To be the Build our next growth engine with consumer-centric healthcare leading partner solutions in reimagining local healthcare and Focus the portfolio; optimize capital we

  20. Slide 20: Transform and Align the Core

    Building the pharmacy of the Transform and Align the Core future to support and enable our healthcare strategy Transform and align the core Reimagining retail through expanded health and wellness offerings and mass Build our next growth engine personalization with consumer-centric healthcare solutio

  21. Slide 21: Build Our Next Growth Engine

    Build Our Next Growth Engine Accelerating the path to become a leading provider of local Transform and align the core clinical care services Build our next growth engine Leveraging consumer centric with consumer-centric healthcare technology and our pharmacy solutions network to deliver and enable o

  22. Slide 22: Focus the Portfolio; Optimize Capital Allocation

    Focus the Portfolio; Optimize Capital Allocation Transform and align the core Build our next growth engine Refocusing the portfolio and with consumer-centric healthcare solutions equity investments to prioritize core assets and healthcare Focus the portfolio; ambitions optimize capital allocation Ma

  23. Slide 23: Build High-performance Culture and A Winning Team

    Build High-performance Culture and A Winning Team Transform and align the core Build our next growth engine with consumer-centric healthcare solutions Focus the portfolio; optimize capital allocation Redefining our culture to drive the transformation Build a high-performance culture and a winning te

  24. Slide 24: Transform and Align the Core

    Transform and Align the Core Accelerating our core business John Standley President Walgreens

  25. Slide 25: Empowering chronic customers on their wellness journey

    Empowering chronic customers on their wellness journey Integrated, pharmacy-led, Expanded healthcare omni-channel retail health and services wellbeing destination (including clinical services, U.S. market diagnostics) 6 in 10 90% Adults have of U.S. a chronic healthcare condition spend ~$1T ~$1T TAM

  26. Slide 26: Building the pharmacy of the future

    Building the pharmacy of the future to support and enable our healthcare strategy Be the 1 Low-Cost Provider Reinvent Micro Fulfillment 2 Omni-channel Experience Pharmacy Digital Clinical of the Engagement Outcomes Future Store Role Refresh Expand Accelerate 4 3 Care Model Growth 26 © 2021 Walgreens

  27. Slide 27: Delivering world-class pharmacy operations

    Delivering world-class pharmacy operations Implementing automated central micro fulfillment capability • Freeing capacity to enable value-add healthcare activities • Reduced working capital • Improved cost-to-fill • National coverage by 2024 Expanded centralized services freeing up additional pharma

  28. Slide 28: Reimagining Healthcare for the next era

    Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian

  29. Slide 29: Expanding health system collaboration and specialty capabilities

    Expanding health system collaboration and comprehensive specialty capabilities 70 Health • 26% of health systems systems 175 Walgreens own specialty pharmacy pharmacies on- compared to 9% 87 Health in 2015 site at health systems systems • 75% of all specialty LDD prescriptions originate Access from

  30. Slide 30: Growing beyond core pharmacy dispensing and expanding healthcare services

    Growing beyond core pharmacy dispensing and expanding healthcare services Longer-term: Fundamental Short term: additional shift over vaccination and services through last 18 months testing hub healthcare strategy 30 © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian nce, ce, I In

  31. Slide 31: Expanding robust vaccination and diagnostics offering

    Expanding robust • Vaccinations • Flu, Pneumonia, Shingles, HPV, vaccination and TDAP, COVID-19 diagnostics offering • Diagnostic Testing • COVID-19 • Influenza A/B >40M COVID-19 vaccines administered • Chronic Care Management • Statins • HbA1c >16M COVID-19 • BMI, BP, Colon screening tests provided

  32. Slide 32: Building clinical pharmacy and healthcare services

    Building clinical pharmacy and healthcare services Pay for Performance ~$730B of total health spend is Disease Management attributed to modifiable risk and Care Gap Closures factors concentrated in several chronic conditions Collaborative Care Upwards of $290B in avoidable Practices healthcare costs

  33. Slide 33: Reimagining retail through health and wellness solutions

    Reimagining retail Be the first choice for health and through health and wellness solutions wellness leadership • Fueled by integrated health, pharmacy and accelerated by mass retail personalization and digitalization at personalization every step in the journey • Empowering chronic customers in the

  34. Slide 34: Integrating health, pharmacy and retail personalization

    Integrating health, pharmacy and retail personalization across the customer journey Pharmacy, health Personalized and wellness rewards wellness journeys Omni- Owned channel brand Walgreens Advertising Group Financial Services © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 34

  35. Slide 35: Reimagining Healthcare for the next era

    Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian

  36. Slide 36: Growing new alternative profit businesses

    Growing new alternative profit businesses Pharmacy, health Personalized and wellness rewards wellness journeys Omni- Owned channel brand Walgreens Financial Advertising Group services © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 36

  37. Slide 37: Accelerating our brands and digital offerings

    Accelerating our brands and digital offerings Range of products and services to meet needs Owned Brand $4.7B owned brand in FY22 Innovation 125+ new retail health products in FY22 Grow penetration to 22% by FY24 Integrated pharmacy and omni-channel experience Digital Tailored wellness journey by Off

  38. Slide 38: Accelerating our omni-channel evolution

    Accelerating our omni-channel evolution 100%+ digital sales growth vs. last year in 4Q FY21 >23M same day orders Completed across curbside, drive-thru, delivery © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 38

  39. Slide 39: Accelerating rigorous margin management program

    Accelerating rigorous margin management program Data-driven category management to fund the journey and re-invest in customer value Rigorous management Enhancement of assortment and of value levers Fund Invest space allocation the in Journey Value Direct and indirect Accelerated owned cost improveme

  40. Slide 40: Reimagining our customer experience

    Reimagining our customer experience Driving store refresh Modernizing with Optimize footprint and program to enhance technology to connect real estate expenses to experience and retail with pharmacy maximize access and increase traffic and physical with digital convenience Key messages/proof points

  41. Slide 41: Tangible goals over the next 3 years

    Creating tangible $1B+ 22% $300M+ goals over Additional TCM Owned brands In alternative savings penetration profit income the next 3 years © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 41

  42. Slide 42: Reimagining Healthcare for the next era

    Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 42

  43. Slide 43: Accelerating omni-channel transformation of Boots UK

    Health and beauty website #1 in the UK Accelerating of total sales online for omni-channel Boots UK 20%+ transformation of Boots UK portfolio AOI growth over FY20 2x as business rebounds © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 43 *4Q Data; Online Participation was 20.7% in FY21 an

  44. Slide 44: Transforming Boots UK healthcare through telehealth, testing, vaccines

    ONLINE DOC / Health Hub COVID-19 Testing Vaccines (100+ services) (3M+ delivered) (100+ locations) Transforming Boots UK healthcare through telehealth, testing, and vaccines © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 44

  45. Slide 45: Strengthening our beauty offering

    40%+ of beauty products in the UK purchased at Boots Strengthening our beauty 60+ new beauty brands introduced offering in stores and online Investing to enhance in-store experience with over 100 stores completed © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 45

  46. Slide 46: Growing our beauty brands portfolio

    Growing our beauty brands portfolio in … to become a $1B the U.S., UK, and Internationally… global business by FY23 Delivering $235M sales in the U.S.; largest growth market; +$200M over 3 years $450M in UK sales; accelerating direct-to- consumer offer Expanding our reach in China; Soap & Glory in m

  47. Slide 47: Transformational Cost Management Program

    Transformational Cost Management Program James Kehoe Global Chief Financial Officer WBA

  48. Slide 48: Transformational Cost Management Program achievements and expansion

    ü Transformational Cost Management (TCM) Program achieved $2.0B+ savings goal one year ahead of schedule through strong governance and focused execution Transformational ü Expanding TCM Program and raising savings Cost Management goal to $3.3B by FY24 Program • Higher savings from existing programs

  49. Slide 49: TCMP Success in Accelerating Savings

    TCMP Success in Accelerating Savings Raising the Bar Goal Achieved - 1 Year Ahead of Schedule $2.0B+ $2.1B $1.8B+ $1.5B+ $1.3B $1.0B+ $0.3B Original Goal Target Raised Target Raised Target Raised FY19 FY20 FY21 Dec 2018 Apr 2019 Oct 2019 Jul 2020 • Launched in FY19 with FY22 target of $1.0B+ • FY19

  50. Slide 50: Expanding TCM Program to Fund Future Growth

    Expanding TCM Program to Fund Future Growth TCM Savings Projection $3.3B • Savings target raised to $3.3B $2.1B • Comprehensive funnel of new initiatives $1.3B • Implementation costs expanded to $0.3B $3.6 to $3.9B through FY24 (compared to previous range of $2.1 to $2.3B) FY19 FY20 FY21 FY24F 1 © 2

  51. Slide 51: $3.3B savings target driven by deep funnel of cost initiatives

    $3.3B savings target driven by deep funnel of cost initiatives Smart Spend Smart Org Divisional Zero Based Budgeting and Policies Global Services Expansion Centralized Rx Services Financial Services Products Smart Organization Next AllianceRx Restructure Global Leadership Model Banking Transformatio

  52. Slide 52: Our Next Growth Engine

    Our Next Growth Engine The future of WBA as a healthcare company Roz Brewer Chief Executive Officer WBA

  53. Slide 53: The pandemic affirmed Walgreens as a trusted neighborhood health destination

    The pandemic affirmed 40M+ Walgreens as a trusted COVID-19 vaccines neighborhood health administered ~80k Pharmacists destination highlighting our and pharmacy technicians ability to help our customers across 9k locations manage their health 51% of retail pharmacy customers used 16M+ health and COVI

  54. Slide 54: Healthcare is inherently local

    Healthcare is inherently local, and all communities should have equitable access to care People plus technology deliver better care Developing a Consumer-centric, omni-channel, whole person care, healthcare delivered with privacy and security by design business built upon a core set Payment models a

  55. Slide 55: Introducing our vision

    Introducing… To be the leading partner in reimagining local healthcare and wellbeing for all © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 55

  56. Slide 56: Maximizing Walgreens diverse assets

    Maximizing Walgreens Creating better outcomes for diverse assets to deliver… consumers and partners… Delightful consumer experience with omni- Consumer-centric approach, leveraging channel engagement Walgreens trusted consumer relationships Improving health outcomes and lowering Nationally scaled, l

  57. Slide 57: Consumer Value: orchestrating the consumer journey

    Consumer Value | Orchestrating the consumer journey across the care continuum Post-acute Store Pre-acute Primary Care / Digital Community Specialty Caregivers & Patients Wellness Clinic Home Omni-channel and Personalized Consumer Engagement Platform Engaging consumers | Care team enabled by technolo

  58. Slide 58: Partner Value: improving outcomes and costs for payors and providers

    Partner Value | Bringing solutions to improve outcomes and costs for our payor and provider partners Clinical Outcomes Population Health Enabling Providers Delegated Risk Management Services and New (Primary Care and on Populations Pharmacy Models Specialists) Increasing impact on health outcomes an

  59. Slide 59: Strategic Investments in CareCentrix and VillageMD

    Strategic Investments | Announcing new strategic investments in CareCentrix and VillageMD Taking majority positions in Building upon our portfolio of Post-Acute and Primary Care assets across the care continuum Health Corner Primary Care Infusion therapies Complex and home care (home and outpatient)

  60. Slide 60: Transforming the post-acute care journey

    Transforming the post-acute care journey from hospital to home Delivering better health outcomes and enhanced patient experience while lowering costs and improving outcomes Scale Outcomes Lives under management Lower readmissions 19M 15-22% Lower emergency Spend under management ~$1.4B 11% departmen

  61. Slide 61: VillageMD primary care delivery platform

    Provides WBA with a best-in-class primary care delivery platform • VillageMD is a leading Primary care is a consumer-focused gateway to the healthcare company 1.6M+ healthcare system Patients 200+ • Superior health Clinics outcomes for patients 300k+ Over $1.4T in Value-Based Lives addressable • Ser

  62. Slide 62: Reimagining Healthcare for the next era

    Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian

  63. Slide 63: Building consumer-centric healthcare platform: Health Corner

    Building and operationalizing our consumer-centric healthcare platform Health Corner DIGITAL ENGAGEMENT PHYSICAL ENGAGEMENT Empowering people to take control of their Taking the digital experience to the next level health by connecting the dots between their by offering in-person advice and expertis

  64. Slide 64: Walgreens Health Corner – Digital channel

    Introducing Walgreens Health Corner – Digital channel CONSUMER and CAREGIVER APP HEALTH MARKETPLACE Increasing engagement Curated and personalized and improving access products and services, covered by insurance Members are supported with simple nudges, Enabling clinicians to friendly reminders, and

  65. Slide 65: Walgreens Health Corner – Physical channel

    Introducing Walgreens Health Corner – Physical channel Health Corners provide a differentiated space to deliver individualized clinical and non-clinical services PHYSICAL SPACE TECH BAR HEALTH ADVISOR Access to personalized, clinical Continuing education for Keeping the member expertise from license

  66. Slide 66: Contracting with key payors across the industry

    Contracting with key payors across the industry ~60K Medicare lives ~1.8M Commercial Lives Operational access to lives Rapidly expanding access to lives Health Corners operational Health Corners planned for ~40 200+ in market California market - at scale Customer interactions Walgreens Digital Healt

  67. Slide 67: Reimagining Healthcare for the next era

    Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences © © 2 20 02 21 1 W Wa alg lgr re een ens s B Boot oots s A Allia llian

  68. Slide 68: Measuring success of Walgreens Health

    Measuring success of Walgreens Health Future Performance * Lives Partners Sites of Care Metrics 2022: 2022: Walgreens Health Corners: Consumer Experience 2M+ 5 payor/ 100+ by YE22 1,200+ in 5 years (Physical and provider 3,000 at scale Digital) 2025: 2025: VillageMD Co-located Clinics: Consumer Expe

  69. Slide 69: Creating a differentiated consumer-centric healthcare business

    Creating a differentiated physical and digital Introducing: Walgreens Health consumer-centric healthcare business ü 2 new strategic investments in care delivery ü Walgreens Digital and Physical Health Corners operationalized ü Key strategic contracts in place with 2 partners with 1.8M+ lives under c

  70. Slide 70: Focus the Portfolio

    Focus the Portfolio Connecting investments and capital to strategy James Kehoe Global Chief Financial Officer WBA

  71. Slide 71: Refined Capital Allocation principles

    Refined Capital Allocation principles, with sharper focus ü on U.S. and healthcare Refocus Portfolio transformation started: Alliance Healthcare ü the portfolio divestiture for $6.5B proceeds and equity Optimize our portfolio of equity investments investments ü • Realign positions with strategy and

  72. Slide 72: Capital allocation priorities sharpened to align with strategy

    Capital allocation priorities sharpened to align with strategy • Healthy balance of organic investments and strategic M&A Capital • Dividends increase over time allocation • Return excess cash to shareholders (investment grade rating) priorities • Optimize portfolio of equity investments • Investmen

  73. Slide 73: Plan to unlock value from equity investments

    Comprehensive plan to unlock value from equity investments; announced CareCentrix and VillageMD strategy Priorities Recent Portfolio Actions • Streamline equity investments • Alliance Healthcare divested $6.5Bn to align with growth strategy and • iA: core pharmacy operating model synergy potential •

  74. Slide 74: Deployed $5.5B to take majority positions in care delivery assets

    Deployed capital of $5.5B to take majority positions in attractive care delivery assets VillageMD CareCentrix • $5.2B investment to raise stake to 63% • ~$330M investment for a 55% initial stake; $800M enterprise value • Leading value-based primary care provider with 230 clinics in 15 markets and gr

  75. Slide 75: Portfolio of investments with ~$21B valuation

    1 Attractive portfolio of investments with ~$21B valuation; streamlining positions to maximize returns U.S. Healthcare Investments: $19.3 - $20.5B Other Investments: $1.3 - $1.5B (1) Estimated valuation based on: (A) publicly traded companies valued based on market price as of 10/4 and (B) and priva

  76. Slide 76: Culture and Team

    Culture and Team Enabling through a high-performing culture Roz Brewer Chief Executive Officer WBA

  77. Slide 77: Clarifying our core values

    OUR HOW Clarifying our core values to enable the transformation Courageous Connected Committed Curious © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 77

  78. Slide 78: Hiring best-in-class talent

    DANIELLE GRAY HOLLY MAY Chief Legal Officer, Chief Human Resources WBA Officer, WBA Prior Experience: Prior Experience: BC NC, White House Starbucks, Abercrombie Hiring ANITA ALLEMAND best-in-class Chief Transformation and Integration Officer, WBA Prior Experience: talent to Optum, CVS Health accele

  79. Slide 79: FY21 / 4Q Earnings

    FY21 / 4Q Earnings James Kehoe Global Chief Financial Officer WBA

  80. Slide 80: FY21 and 4Q financial highlights

    FY21 and 4Q financial highlights • Strong finish to the year, exceeded expectations • 4Q continuing operations adj. EPS $1.17, +28.1% above prior year in constant Fx • FY21 continuing operations adj. EPS $4.91, +13.7% above prior year in constant Fx • Includes 34.6 million doses of COVID-19 vaccines

  81. Slide 81: FY21 and 4Q financial highlights

    FY21 and 4Q financial highlights • 4Q results reflected strong execution across the board • U.S. comparable scripts +8.8%, boosted by COVID-19 vaccines +485bps; 21% share of 4Q vaccinations • U.S. retail comp sales growth +6.2%, +7.2% excl. tobacco and e-cig • UK recovery on track and regaining mark

  82. Slide 82: Continuing adjusted EPS grew +28.1% in 4Q

    Continuing adjusted EPS grew +28.1% in 4Q; +13.7% in FY21 B/(W) vs. 4Q20 B/(W) vs. FY20 Results 4Q21 FY21 $ in millions (except EPS) Reported Fx Constant Fx Reported Fx Constant Fx Sales (continuing) $34,262 + 12.8% + 11.8% $132,509 + 8.6% + 7.5% Operating income (continuing) GAAP $910 + 49.7% $2,34

  83. Slide 83: Adjusted 4Q21 AOI growth of 22%

    Adjusted 4Q21 AOI growth of 22% led by strong adjusted gross profit growth in both segments 4Q21 FY21 Results $ in millions WBA U.S. Intl WBA U.S. Intl Sales (continuing) $34,262 $28,755 $5,507 $132,509 $112,005 $20,505 % B/(W) vs. prior year + 11.8% + 6.6% + 52.6% + 7.5% + 4.0% + 34.1% Adjusted gro

  84. Slide 84: Long-Term Growth

    Long-Term Growth Reimagining Healthcare for the next era a

  85. Slide 85: Long-term EPS growth algorithm in the low teens

    Long-term EPS growth algorithm in the low teens, driven by advantaged healthcare business and moderate core growth Long Term Growth Algorithm highly influenced by pace of healthcare ü investments and capital allocation (organic vs inorganic) • 3 reporting segments in FY22: U.S., International, Walgr

  86. Slide 86: Long-term growth – Corporate Assumptions

    Long-term growth – Corporate Assumptions Tax rate trending higher (mix, higher rate U.S. income); FY22 16%, ü Rising FY23 18.5%, FY24 20%, +50bps per annum thereafter Tax Rate Implications of current legislative proposals not considered ü Limited Share Not a priority in the short-term, focus on cred

  87. Slide 87: Long-term growth – International Segment Assumptions

    Long-term growth – International Segment Assumptions AOI growth of >50% in FY22, with sales up +8-10% ü Strong AOI • Led by Boots UK strength, with AOI growing +55-60% growth over next 3 years International 3-yr AOI CAGR +25-30%: sales CAGR of +4-5% ü • Led by Boots UK 3-year AOI CAGR of >25% Sales

  88. Slide 88: Long-term growth – U.S. Segment Assumptions

    Long-term growth – U.S. Segment Assumptions Vaccinations FY21: 34.6M, FY22: ~25M ü Minimum Wage (gross impact): $(450)M over three years Headwinds ü AllianceRx (ARxWP): Sales $(8)B, AOI $(100)M in FY22 ü Retail momentum exiting FY21, ROI on omni-investments ü Tailwinds New business: Financial servic

  89. Slide 89: Long-term growth – Walgreens Health Segment Assumptions

    Long-term growth – Walgreens Health Segment Assumptions Sizeable sales potential: ü • Walgreens Health organic sales potential of at least $3.5B • M&A sales outlook (CCX, VMD, Shields): FY22 ~$3B, FY25 $9-10B Attractive margin profile, above base WBA business ü EPS impact is material to WBA, contrib

  90. Slide 90: Long-term algorithm shows EPS growth accelerating to low teens

    Long-term algorithm shows EPS growth accelerating to low teens, as healthcare segment scales up and margins build Next LT-growth 3-years algorithm (FY25+) 4.5% 2.5-3% Base Healthcare 0.5% 6.5-7.5% (1)% (1)% Tax rate Share repurchases -% 3.0-3.5% EPS growth % (constant Fx) ~4% 11-13% 90 Note: All ref

  91. Slide 91: FY22 Guidance

    FY22 Guidance Reimagining Healthcare for the next era a

  92. Slide 92: FY22 base growth of 4% and headwinds

    Base growth of 4% includes over 8%p of headwinds, primarily from vaccines (4%p) and growth investments (3%p) FY22 EPS GROWTH DRIVERS OF BASE GROWTH: +4% Base +4% Vaccines and testing (4) Healthcare Organic (3)% Higher investments (3) Healthcare M&A (1)% Minimum wage (1) ABC equity earnings 4 Interna

  93. Slide 93: Organic healthcare investment in FY22

    Organic healthcare investment of $(210)-$(230)M in FY22, reduces EPS growth by 3%p FY22 EPS GROWTH WALGREENS HEALTH ORGANIC FY22: Base +4% Healthcare Organic (3)% AOI ($ M) $ (210)-(230) Healthcare M&A (1)% EPS $ (0.18) – (0.21) Adjusted EPS: flat Note: All references to EPS or EPS growth refer to A

  94. Slide 94: Healthcare M&A dilutive in FY22

    Healthcare M&A will be ($0.05) to ($0.10) cents dilutive in FY22 FY22 EPS GROWTH HEALTHCARE M&A FY22: Base +4% Healthcare Organic (3)% Healthcare M&A (1)% Sales ($ B) $ 3.0-3.2 EPS $ (0.05) - $(0.10) Adjusted EPS: flat Note: All references to EPS or EPS growth refer to Adjusted Continuing EPS at con

  95. Slide 95: Strong start – 1H EPS growth +15-18%

    Expecting strong start – 1H EPS growth +15-18%; full year base growth tempered by investments / lapping vaccines FY22 EPS GROWTH 1H: +15-18% Base +4% Lapping weak FY21 C/C/Flu Healthcare Organic (3)% Higher vaccines 1H22 Healthcare M&A (1)% 2H: (14)-(17)% Tough prior year comps (vaccinations) Adjust

  96. Slide 96: Long-term algorithm shows EPS growth accelerating to low teens

    Long-term algorithm shows EPS growth accelerating to low teens, as healthcare segment scales up and margins build Next LT-growth 3-years algorithm (FY25+) 4.5% 2.5-3% Base Healthcare 0.5% 6.5-7.5% (1)% (1)% Tax rate Share repurchases -% 3.0-3.5% EPS growth % (constant Fx) ~4% 11-13% 96 Note: All ref

  97. Slide 97: Closing Comments and Future Outlook

    Closing Comments and Future Outlook Roz Brewer Chief Executive Officer WBA

  98. Slide 98: Future growth driven by advantaged healthcare position

    Future growth to be driven by our advantaged healthcare position Model shows accelerating EPS growth as WBA pivots deeper into ü healthcare and creates an innovative and advantaged business model EPS growth at ~4% CAGR first 3-years, held back by FY22 investments, ü lower vaccines Long-term growth m

  99. Slide 99: Integrated healthcare, pharmacy and retail strategy summary

    We have an integrated healthcare, pharmacy, and retail strategy, 1 enabling sustainable, profitable growth We are well on our way to our new healthcare vision and ambition 2 We are putting the right capabilities, assets, and operating model in 3 place We are committed to enhanced communication and t

  100. Slide 100: Q&A

    Q&A 100 © 2021 Walgreens Boots Alliance, Inc. All rights reserved.

  101. Slide 101: Reimagining Healthcare for the next era

    Hyper Customer Improving localized centric outcomes Scale and Reimagining momentum Healthcare Transformational partnerships for the next era Investor Day 2021 Lowering cost of care Rx at Delightful the center customer experiences 10 © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 1

  102. Slide 102: Endnotes

    Endnotes ◦ Unless otherwise noted, all prior year numbers have been recast for continuing operations. Refer to WBA's Current Report on Form 8-K filed on March 31, 2021. ◦ Please see appendix for reconciliations of non-GAAP financial measures and related disclosures • The company presents certain inf

  103. Slide 103: Appendix

    Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente

  104. Slide 104: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent

  105. Slide 105: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent

  106. Slide 106: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent

  107. Slide 107: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) DILUTED NET EARNINGS (LOSS) PER SHARE Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent

  108. Slide 108: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) 1 Adjustments to equity earnings (loss) in AmerisourceBergen consist of the Company’s proportionate share of non-GAAP adjustments reported by AmerisourceBe

  109. Slide 109: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended August 31, 2021 Walgreens Boots 1 United States International Corporate and Other Alliance, Inc. Sales $ 28,755 $ 5,507 $ — $ 34,262 Gro

  110. Slide 110: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) Three months ended August 31, 2020 Walgreens Boots (in millions) 1 United States International Corporate and Other Alliance, Inc. Sales $ 26,967 $ 3,403 $ — $ 30,371 Gro

  111. Slide 111: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Twelve months ended August 31, 2021 Walgreens Boots 1 United States International Corporate and Other Alliance, Inc. Sales $ 112,005 $ 20,505 $ — $ 132,509

  112. Slide 112: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Twelve months ended August 31, 2020 Supplemental Information (unaudited) Walgreens Boots (in millions) 1 United States International Corporate and Other Alliance, Inc. Sales $ 107,701 $ 14,281 $ — $ 121,982

  113. Slide 113: Reconciliation of Non-GAAP financial measures: free cash flow

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended August 31, Twelve months ended August 31, 2021 2020 2021 2020 Net cash provided by operating activities (GAAP) $ 1,245 $

Walgreens Boots Alliance — Investor Day (October 2021) on 6ix